Vion Pharmaceuticals ( VION) shot up in heavy premarket trading Monday after the FDA granted fast-track status to its leukemia treatment candidate.

The company's Cloretazine, a drug for refractory acute myeloid leukemia, will be considered under the fast-track designation, which is designed to facilitate the development and expedite the review of new drugs that are intended to treat serious or life-threatening conditions.

The shares shot up 49 cents, or $13.6%, to $4.09 after the news was released. Vion was the most actively traded issue on the Instinet premarket session.

More from Opinion

It's Just Not Smart For Investors to Ignore the Threat of a Trade War

It's Just Not Smart For Investors to Ignore the Threat of a Trade War

To Think a Trade War's Still Just a Threat Is the Dumbest Thing on Wall Street

To Think a Trade War's Still Just a Threat Is the Dumbest Thing on Wall Street

Flashback Friday in Politics: Trade Wars, Manafort, Immigration Dominate Minds

Flashback Friday in Politics: Trade Wars, Manafort, Immigration Dominate Minds

Microsoft and Sony's Rumored Game Console Plans Bode Well for AMD

Microsoft and Sony's Rumored Game Console Plans Bode Well for AMD

Apple Supplier Jabil Is Tumbling, But Its Sales Momentum Remains Strong

Apple Supplier Jabil Is Tumbling, But Its Sales Momentum Remains Strong